Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

This study aimed to evaluate the use of testosterone replacement therapy (TRT) in men who had definitive treatment for prostate cancer. The authors concluded that TRT was not associated with a higher risk of recurrence in these patients.

Prostate cancer (PCa) is commonly fueled by the sex hormone testosterone. PCa treatment can cause a lack of testosterone. A lack of testosterone can lead to insomnia, low mood and low libido. Medication can be taken to replace the hormone (TRT; testosterone replacement therapy). However, the oncological safety of TRT in patients who have undergone definitive treatment for PCa is still unknown.

This study included data from 21 other articles. All patients had localized PCa. These men received TRT after treatment for PCa. They had treatment if they had symptoms of low testosterone. They had to have no evidence of active cancer. The risk of recurrence was evaluated.

There was no association between having TRT and recurrence of PCa. This was true for patients who had prostate surgery, radiotherapy, cryotherapy or high-intensity focused ultrasound as a treatment for PCa.

This study concluded that TRT does not seem to be associated with a higher risk of recurrence in patients who had definitive treatment for localized PCa.

Most studies included were based on medical records. Data collected in this way is not always the best evidence. Further research is needed.

If you have concerns about low testosterone levels and PCa recurrence, please consult with your doctor.